Literature DB >> 721701

Topographical organization of the striatonigral pathway revealed by anterograde and retrograde neuroanatomical tracing techniques.

I F Tulloch, G W Arbuthnott, A K Wright.   

Abstract

L-[4,5-3H]leucine was injected stereotaxically into various regions of the rat neostriatum. Light microscopic autoradiographic techniques were used to plot the entire efferent pathways of the neostriatum, and in particular, the projections to the substantia nigra (SN). The terminal distribution of the pathways projecting to the ipsilateral SN was predominantly restricted to the zona reticulata region. The dorsal part of the head of the striatum was found to innervate the anterior and medial portions of the zona reticulata, while the ventral area of the head projected to more posterior regions of the SN. A pathway from the tail of the striatum to the lateral and dorsal parts of SN was also demonstrated. Horseradish peroxidase injections, restricted to different areas of the SN, led to retrograde labelling of neurons in the striatum whose distribution confirmed the topographic organization of the striatonigral pathway demonstrated in the autoradiographic studies.

Entities:  

Mesh:

Year:  1978        PMID: 721701      PMCID: PMC1235782     

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  37 in total

1.  An experimental study of the course and destination of fibers arising in the head of the caudate nucleus in the cat and monkey.

Authors:  T J VONEIDA
Journal:  J Comp Neurol       Date:  1960-08       Impact factor: 3.215

2.  Stereotaxic mapping of the monoamine pathways in the rat brain.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

3.  An experimental electron microscopic study on the striatonigral projection in the cat.

Authors:  I Grofová; E Rinvik
Journal:  Exp Brain Res       Date:  1970       Impact factor: 1.972

4.  Projections of substance P containing neurons from neostriatum to substantia nigra.

Authors:  J S Hong; H Y Yang; G Racagni; E Costa
Journal:  Brain Res       Date:  1977-02-25       Impact factor: 3.252

5.  Inhibition of substance P release from the isolated rat substantia nigra by GABA [proceedings].

Authors:  T M Jessell; L L Iversen
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

6.  Evidence for the existence of substance P-containing fibres in striato-nigral and pallido-nigral pathways in rat brain.

Authors:  I Kanazawa; P C Emson; A C Cuello
Journal:  Brain Res       Date:  1977-01-07       Impact factor: 3.252

7.  Feedback loop or output pathway in striato-nigral fibres?

Authors:  M Garcia-Munoz; M N Nicolaou; I F Tulloch; A K Wright; G W Arguthnott
Journal:  Nature       Date:  1977-01-27       Impact factor: 49.962

8.  A Golgi study of neuronal types in the neostriatum of monkeys.

Authors:  M DiFiglia; P Pasik; T Pasik
Journal:  Brain Res       Date:  1976-09-17       Impact factor: 3.252

9.  Afferents to the rat substantia nigra studied with horseradish peroxidase, with special reference to fibres from the subthalamic nucleus.

Authors:  I Kanazawa; G R Marshall; J S Kelly
Journal:  Brain Res       Date:  1976-10-22       Impact factor: 3.252

10.  The topographical distribution of serotoninergic terminals in the neostriatum of the rat and the caudate nucleus of the cat.

Authors:  J P Ternaux; F Héry; S Bourgoin; J Adrien; J Glowinski; M Hamon
Journal:  Brain Res       Date:  1977-02       Impact factor: 3.252

View more
  14 in total

1.  Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.

Authors:  I Christensson-Nylander; M Herrera-Marschitz; W Staines; T Hökfelt; L Terenius; U Ungerstedt; C Cuello; W H Oertel; M Goldstein
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

Review 2.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

3.  Oral behaviour induced by intranigral muscimol is unaffected by haloperidol but abolished by large lesions of superior colliculus.

Authors:  E B Taha; P Dean; P Redgrave
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Non-dopamine containing efferents of substantia nigra: the pathway to the lower brain stem.

Authors:  A K Wright; G W Arbuthnott
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

5.  Dysfunction of the midbrain angular complex can accentuate or attenuate circling behaviour in the rat.

Authors:  M S Starr; M Summerhayes
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

6.  Amygdalo-striatal interaction in the enhancement of stimulus salience in associative learning.

Authors:  Guillem R Esber; Karina Torres-Tristani; Peter C Holland
Journal:  Behav Neurosci       Date:  2015-03-02       Impact factor: 1.912

7.  Interactions between the Midbrain Superior Colliculus and the Basal Ganglia.

Authors:  Peter Redgrave; Veronique Coizet; Eliane Comoli; John G McHaffie; Mariana Leriche; Nicolas Vautrelle; Lauren M Hayes; Paul Overton
Journal:  Front Neuroanat       Date:  2010-09-22       Impact factor: 3.856

8.  Posterior parietal cortex is critical for the encoding, consolidation, and retrieval of a memory that guides attention for learning.

Authors:  Felipe L Schiffino; Vivian Zhou; Peter C Holland
Journal:  Eur J Neurosci       Date:  2013-11-15       Impact factor: 3.386

Review 9.  Dorsal and ventral streams: the distinct role of striatal subregions in the acquisition and performance of goal-directed actions.

Authors:  Genevra Hart; Beatrice K Leung; Bernard W Balleine
Journal:  Neurobiol Learn Mem       Date:  2013-11-11       Impact factor: 2.877

10.  Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons.

Authors:  H Moore; C L Todd; A A Grace
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.